Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Experimental immunotherapies for multiple sclerosis

R Martin1, H McFarland

  • 1Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD 20892, USA.

Springer Seminars in Immunopathology
|January 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Manganese-Enhanced MRI in Patients with Multiple Sclerosis.

AJNR. American journal of neuroradiology·2020
Same author

Intrathecal effects of daclizumab treatment of multiple sclerosis.

Neurology·2011
Same author

The role of radiotracer imaging in Parkinson disease.

Neurology·2005
Same author

Interferon beta-1b in secondary progressive MS: a combined analysis of the two trials.

Neurology·2004
Same author

Estimating cerebral atrophy in multiple sclerosis patients from various MR pulse sequences.

Multiple sclerosis (Houndmills, Basingstoke, England)·2002
Same author

A pilot study of recombinant insulin-like growth factor-1 in seven multiple sderosis patients.

Multiple sclerosis (Houndmills, Basingstoke, England)·2002
Same journal

Antibody and complement-dependent viral neutralization.

Springer seminars in immunopathology·2020
Same journal

Antibody mediated complement dependent lysis of virus infected cells.

Springer seminars in immunopathology·2020
Same journal

Activating and inhibitory FcgammaRs in autoimmune disorders.

Springer seminars in immunopathology·2006
Same journal

Injecting drugs of abuse and immunity: implications for HIV vaccine testing and efficacy.

Springer seminars in immunopathology·2006
Same journal

Fcepsilon- and Fcgamma-receptor signaling in diseases.

Springer seminars in immunopathology·2006
Same journal

Fc gamma receptors and cancer.

Springer seminars in immunopathology·2006
See all related articles

Multiple sclerosis (MS) research explores autoimmune T cells targeting the central nervous system (CNS). While animal models show promise, human MS studies reveal less specific T cell involvement, shifting focus to novel immunotherapies.

Area of Science:

  • Neuroimmunology
  • Autoimmune diseases
  • Central Nervous System (CNS) disorders

Background:

  • Multiple Sclerosis (MS) is a chronic CNS demyelinating disease primarily affecting young adults.
  • Current evidence suggests autoimmune T cells mediate tissue damage, with myelin basic protein (MBP) and proteolipid protein (PLP)-specific T cells implicated in animal models (EAE).
  • Encephalitogenic T cells in EAE recognize specific peptides within MHC/HLA-class II contexts, utilize restricted T cell receptors (TCRs), and secrete inflammatory cytokines.

Purpose of the Study:

  • To review the understanding of pathogenetic steps in MS lesion development.
  • To evaluate the applicability of EAE-derived immunotherapies to human MS.
  • To discuss emerging strategies for MS immunotherapy, focusing on modifying lesion biology.

Main Methods:

Related Experiment Videos

  • Examination of experimental allergic encephalomyelitis (EAE) as an animal model for MS.
  • Analysis of T cell responses to myelin antigens (MBP, PLP) in MS patients and controls.
  • Review of immunotherapies targeting the trimolecular complex (TMC) and lesion modification strategies.

Main Results:

  • While MBP- and PLP-specific T cells are found in MS patients, their specificity and TCR usage are variable and not unique to MS, unlike in EAE models.
  • Evidence for a singular immunological abnormality in MS remains limited.
  • Interferon-beta has demonstrated efficacy in modifying lesion development in relapsing-remitting MS.

Conclusions:

  • Directly targeting myelin-specific T cells or the trimolecular complex (TMC) in MS has faced challenges due to variable T cell involvement.
  • The focus is shifting towards modifying the biology of MS lesions rather than solely targeting initiating events.
  • Interferon-beta's success validates approaches that modify disease processes, encouraging the development of novel immunotherapies for MS.